Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were designed to allow specific targeting of highly potent cytotoxic agents to tumor cells whilst sparing normal cells. Frequent toxic...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Taylor & Francis
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966843/ |